Vilket är priset för CARsgen Therapeutics Holdings Limited (2171)

Priset för CARsgen Therapeutics Holdings Limited (2171) är $1.72

Vilket är marknadsvärdet för CARsgen Therapeutics Holdings Limited (2171)

Marknadsvärdet för CARsgen Therapeutics Holdings Limited (2171) är $981.92M

CARsgen Therapeutics Holdings Limited (2171) P/E-tal

CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in Shanghai, China, in 2014, focuses on the discovery, development, and commercialization of advanced chimeric antigen receptor T (CAR-T) cell therapies. The company's efforts are directed toward treating various hematological malignancies and solid tumors across China and the United States. Its robust pipeline includes several key candidates: CT053, an autologous CAR-T product, is currently in a pivotal Phase II trial in China for relapsed/refractory multiple myeloma. Additionally, CT041, another autologous CAR-T, is undergoing Phase Ib/II clinical trials for advanced gastric/gastroesophageal junction and pancreatic cancers in China, and Phase Ib trials for comparable indications in the U.S. CARsgen is also advancing CT011, an autologous CAR-T candidate, through Phase I for patients with Glypican-3 positive advanced hepatocellular carcinoma, and CT032, an autologous CAR-T, in Phase I/II for B cell Non-Hodgkin's lymphoma in China. Furthermore, its pipeline features AB011, a humanized monoclonal antibody in Phase I for CLDN18.2 positive solid tumors in China, as well as CT017, an autologous Glypican-3-targeted CAR-T for hepatocellular carcinoma, and other promising therapies for solid tumors.

År	P/E-tal	Ändra
Inte tillräckligt med data för de angivna datumen.

År

P/E-tal

Ändra

Inte tillräckligt med data för de angivna datumen.

Företag	P/E-tal	Skillnad i P/E-tal	Land
Vertex Pharmaceuticals Incorporated VRTX.US	29.20	-	US
Argenx SE ARGX.US	30.62	-	NL
CSL Limited CSL.AX	32.46	-	AU
Moderna, Inc. MRNA.US	-7.93	-	US
Lonza Group AG LONN.SW	-	-	CH

Företag

P/E-tal

Skillnad i P/E-tal

Land